Today we announced to the market that Jenn Chow has given notice of her resignation as Managing Director and Chief Executive Officer of the Company. It is expected that Jenn will leave the company later this month.
The Board is taking the opportunity refocus the Company's management in Australia, with further announcements on this expected in the very near term.
I want to reassure everyone our programs are on track and we remain enthusiastic about the technology platforms – including the CDH 17 program from University of Pennsylvania which we look forward to providing updates on soon.
As a result of the collective efforts of Jenn and the team, the Company has a strong foundation of cell therapy assets that positions it well for ongoing clinical development.
The Board acknowledges the major contributions made by Jenn and wishes her well in all future endeavours.
Regards
Paul Hopper Executive Chairman
CHM Price at posting:
2.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)